UNSPSC 51111733: Bleomycin

This classification denotes a bleomycin antibiotic with the molecular formula C55H84N17O21S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40S1VHN69B, more generally known as bleomycin. European Medicines Agency schedules bleomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00842MIG. The term BLEOMYCIN is an International Non-Proprietary Name or INN. Most nations schedule bleomycin under HS 29419000 and SITC 54139. As of Q4 2014, BLEOMYCIN remains the US FDA Preferred Term for this commodity.

Bleomycin bears US NLM identifiers UMLS ID C0005740 and NCI Concept Code C313. SMILES: CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O.

UNSPSC 51111733 Bleomycin, a Commodity code, shows minimal relevant recent state and local procurement activity. The two opportunities posted under this code in the source do not reflect purchases of bleomycin or chemotherapy agents; instead, they document a completed pharmaceutical warehouse contract for antibiotics (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) awarded by the Illinois Department of Public Health to Chartwell Rx LLC, and a Seminole County, Florida procurement for naloxone and drug deactivation systems. Neither aligns with the code's nominal scope of bleomycin, a cytotoxic chemotherapy drug. The mismatch suggests either miscoding at the point of solicitation or that bleomycin procurement through state and local channels does not currently generate publicly visible bidding activity. Health departments, county health agencies, and other state and local entities that might source oncology pharmaceuticals do not appear in the recent opportunity record under this code.

Without substantive recent opportunities matching bleomycin's actual scope, assessment of issuing-body concentration, geographic spread, or contract patterns is not supported by the source. Vendors pursuing bleomycin sales to state and local buyers should verify coding alignment at the point of RFP or cooperative purchasing vehicle enrollment, and monitor oncology or pharmacy purchasing channels directly rather than relying on this code as a discovery tool.